These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25182571)

  • 21. Identification of treatment responders based on multiple longitudinal outcomes with applications to multiple sclerosis patients.
    Kondo Y; Zhao Y; Petkau J
    Stat Med; 2017 May; 36(12):1862-1883. PubMed ID: 28147439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies.
    Tang Y; Cai C; Sun L; He J
    J Biopharm Stat; 2017; 27(6):975-989. PubMed ID: 28318420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting event times in clinical trials when treatment arm is masked.
    Donovan JM; Elliott MR; Heitjan DF
    J Biopharm Stat; 2006 May; 16(3):343-56. PubMed ID: 16724489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continual reassessment method: a likelihood approach.
    O'Quigley J; Shen LZ
    Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inference of equivalence for the ratio of two normal means with unspecified variances.
    Xu S; Hua SY; Menton R; Barker K; Menon S; D'Agostino RB
    J Biopharm Stat; 2014; 24(6):1264-79. PubMed ID: 25033269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
    Thomas N
    J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal and repeated cross-sectional cluster-randomization designs using mixed effects regression for binary outcomes: bias and coverage of frequentist and Bayesian methods.
    Localio AR; Berlin JA; Have TR
    Stat Med; 2006 Aug; 25(16):2720-36. PubMed ID: 16345043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Empirical Bayes estimates for correlated hierarchical data with overdispersion.
    Iddi S; Molenberghs G; Aregay M; Kalema G
    Pharm Stat; 2014; 13(5):316-26. PubMed ID: 25181392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian analysis of nonlinear mixed-effects mixture models for longitudinal data with heterogeneity and skewness.
    Lu X; Huang Y
    Stat Med; 2014 Jul; 33(16):2830-49. PubMed ID: 24623529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
    Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
    Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies.
    Huang Y; Dagne G
    Stat Med; 2010 Oct; 29(23):2384-98. PubMed ID: 20603815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of an outcome using trajectories estimated from a linear mixed model.
    Maruyama N; Takahashi F; Takeuchi M
    J Biopharm Stat; 2009 Sep; 19(5):779-90. PubMed ID: 20183443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trial.
    Habteab Ghebretinsae A; Molenberghs G; Dmitrienko A; Offen W; Sethuraman G
    J Biopharm Stat; 2014; 24(3):660-84. PubMed ID: 24697817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
    Thall PF; Nguyen HQ; Braun TM; Qazilbash MH
    Biometrics; 2013 Sep; 69(3):673-82. PubMed ID: 23957592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.